← Drug database

Clopidogrel BMS (clopidogrel)

Region
🇪🇺 EU
Active substance
clopidogrel
Company
Bristol-Myers Squibb Pharma EEIG
Status
Withdrawn
Therapeutic area
Stroke; Peripheral Vascular Diseases; Myocardial Infarction; Acute Coronary Syndrome
EU approval
Wed 16 Jul 2008
Application
EMEA/H/C/000974
ATC
B01AC04
Official record
www.ema.europa.eu

Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: - Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. - Patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Clopidogrel BMS

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.